New approaches in identifying drugs to inactivate oncogene products.
With an information explosion on the molecular mechanism of oncogenesis, the completion of the human genome sequence project, and the advances in genomic and proteomic methods, many therapeutic targets for various cancers have been identified. It is timely that a number of new drug development techniques have been developed in this last decade. Candidate drug targets can now be efficiently validated with RNA interference and transgenic animals studies. Combinatorial chemistry provides large numbers of chemical compounds for drug lead discovery and optimization. High throughput assays and high content cell-based assays, in conjunction with sophisticated robotics, are now available for screening large numbers of compounds. Based on X-ray crystallographic structure data, drug leads can be discovered through in silico screening of virtual libraries. By applying these various drug discovery techniques, it is anticipated that more potent and specific anti-cancer agents will be discovered within the next decade.
Liu
Ruiwu
R
Division of Hematology & Oncology, Department of Internal Medicine, UC Davis Cancer Center, University of California at Davis, 4501 X Street, Sacramento, CA 95817, USA.
Hsieh
Ching-Yi
CY
Lam
Kit S
KS
D020650:Combinatorial Chemistry Techniques; D017076:Computer-Aided Design; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D015513:Oncogene Proteins